JP2025513802A5 - - Google Patents
Info
- Publication number
- JP2025513802A5 JP2025513802A5 JP2024559468A JP2024559468A JP2025513802A5 JP 2025513802 A5 JP2025513802 A5 JP 2025513802A5 JP 2024559468 A JP2024559468 A JP 2024559468A JP 2024559468 A JP2024559468 A JP 2024559468A JP 2025513802 A5 JP2025513802 A5 JP 2025513802A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- cell carcinoma
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329104P | 2022-04-08 | 2022-04-08 | |
| US63/329,104 | 2022-04-08 | ||
| PCT/US2023/017254 WO2023196218A2 (en) | 2022-04-08 | 2023-04-03 | Combination therapies comprising a sos1 inhibitor and a mek inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513802A JP2025513802A (ja) | 2025-04-30 |
| JP2025513802A5 true JP2025513802A5 (https=) | 2026-04-13 |
Family
ID=88243402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559468A Pending JP2025513802A (ja) | 2022-04-08 | 2023-04-03 | Ｓｏｓ１阻害剤及びｍｅｋ阻害剤を含む併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186453A1 (https=) |
| EP (1) | EP4504197A4 (https=) |
| JP (1) | JP2025513802A (https=) |
| KR (1) | KR20250002214A (https=) |
| CN (1) | CN118973580A (https=) |
| AU (1) | AU2023250314A1 (https=) |
| CA (2) | CA3245730A1 (https=) |
| IL (1) | IL315648A (https=) |
| MX (1) | MX2024012446A (https=) |
| WO (1) | WO2023196218A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558979B1 (en) * | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| PH12022551513A1 (en) * | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| AU2021263742A1 (en) * | 2020-04-27 | 2022-09-22 | Verastem, Inc. | Methods of treating abnormal cell growth |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| WO2022051568A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
| US12280055B2 (en) * | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3221608A1 (en) * | 2021-06-14 | 2022-12-22 | Kumquat Biosciences Inc. | Fused heteroaryl compounds useful as anticancer agents |
| WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
-
2023
- 2023-04-03 AU AU2023250314A patent/AU2023250314A1/en active Pending
- 2023-04-03 WO PCT/US2023/017254 patent/WO2023196218A2/en not_active Ceased
- 2023-04-03 KR KR1020247033661A patent/KR20250002214A/ko active Pending
- 2023-04-03 IL IL315648A patent/IL315648A/en unknown
- 2023-04-03 EP EP23785216.5A patent/EP4504197A4/en active Pending
- 2023-04-03 US US18/852,225 patent/US20250186453A1/en active Pending
- 2023-04-03 CA CA3245730A patent/CA3245730A1/en active Pending
- 2023-04-03 JP JP2024559468A patent/JP2025513802A/ja active Pending
- 2023-04-03 CN CN202380032771.6A patent/CN118973580A/zh active Pending
- 2023-04-03 CA CA3255758A patent/CA3255758A1/en active Pending
-
2024
- 2024-10-07 MX MX2024012446A patent/MX2024012446A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537140A5 (https=) | ||
| JP2025000632A5 (https=) | ||
| JP2025000629A5 (https=) | ||
| JP2022548791A5 (https=) | ||
| JP2025512999A5 (https=) | ||
| JP2025000630A5 (https=) | ||
| JP2024521788A5 (https=) | ||
| JP2024537136A5 (https=) | ||
| JP2024537139A5 (https=) | ||
| HRP20250059T1 (hr) | Kombinirane terapije | |
| JP2024537137A5 (https=) | ||
| JP2022548255A5 (https=) | ||
| JP2023540809A5 (https=) | ||
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| CN102178894B (zh) | 一种治疗腰椎间盘突出、骨质增生、关节炎、股骨头无菌坏死和跌打损伤的膏药及其制备方法 | |
| JP2024540839A5 (https=) | ||
| HRP20230377T1 (hr) | Inhibitori mutacije kras g12c | |
| IL315645A (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor | |
| JP2025513802A5 (https=) | ||
| JP2022530866A5 (https=) | ||
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods | |
| JP6309009B2 (ja) | 前立腺の治療のための薬物送達システム及び方法 | |
| JP2022535577A5 (https=) | ||
| JP2013523683A5 (https=) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 |